ClinicalTrials.gg
RecruitingNCT06871384WinAgingUpdated Mar 5, 2026

Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects

An interventional study of Nonalcoholic red wine group (Intervention group) and Drinking water group (Control group) in Cognitive Disorders and Muscular Disorders, Atrophic, sponsored by University Rovira i Virgili. Recruiting at 3 sites in Spain. Open to participants aged 60 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University Rovira i Virgili · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
60 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Planned enrollment
88th of 127
72 · median 100
Started
2025
with 15 others
No phase
91 of 162
27 open now
Primary completion
2026-09
later than 23 of 60 live
Registered
128th of 162
by date

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 88th largest by planned enrollment of the 127 interventional ones that give a count, is one of 16 that started in 2025, is one of 91 with no phase, reaches primary completion later than 23 of the 60 other live ones, and was the 128th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

Polyphenols, precisely resveratrol, with red wine as the most substantial source, was associated with improvements in cognitive function. Also, the loss of muscle mass and strength in elderly, that significantly increases dependency of these people, it could be attributed to alterations in gut microbiota through the "gut-muscle axis" and this underline the urgent need to efficiently find out any intervention or preventive approach via modulation of gut microbiota to improve muscle function in elderly. In this context, red wine polyphenols exert their effects through interaction with gut microbiota following the well-known two-way interaction between polyphenols and gut microbiota by promoting the proliferation of beneficial bacteria and increasing their abundance. Similarly, aging cognitive decline can be modulate by microbiota, notably through "gut-brain axis". Additionally, dietary polyphenols can delay inflammation or/and oxidation on the onset of age-related cognitive decline or muscular oxidation or cardiovascular factors risk factors, all of them relevant factors for the onset of physical frailty and dependence in elderly.

Moreover, wine is a singular alcoholic beverage with a high content of phenolic compounds of a very diverse nature on which numerous protective effects on health have been described. In fact, wine, in addition to alcohol, contains a complex mixture of polyphenols, including anthocyanins and non-coloured phenols as proanthocyanidins, flavonols, hydroxycinnamic and hydroxybenzoic acids, stilbenes and lignans. Thus, the bioprotective effects of wine polyphenols could be the consequence of the synergistic effect of this complex mixture of polyphenols from the grape and the winemaking process. That is why it is essential to clarify whether consumption of polyphenols from red wine provided by a nonalcohol red wine within a healthy diet can produce beneficial effects on health, differentiating this pattern from a general consumption of alcohol generally associated with negative effects. Based on the ethical limitations to carry out diet intervention studies with wine in humans, this project proposes the use of a nonalcoholic wine as vehicle of the complex mixture of red wine polyphenols.

The hypothesis of our research is that regular consumption of red wine polyphenols, 150 mg/day, delivered through a nonalcoholic red wine, in the context of a Mediterranean diet (MD pattern), could promote protective mechanisms for a healthy aging, especially through its beneficial effects on cognitive and locomotor abilities and mediated by the modulation of the intestinal microbiota (composition, function and associated metabolome). The main objective of the WinAging project is to add knowledge concerning the diet modulation of molecular mechanisms of the aging process through multi-omic approaches based on the potential health effects of a dietary strategy by a sustained MD supplementation with nonalcoholic red wine rich in polyphenols to tackle cognitive and locomotor abilities in early elderly home-dwelling subjects.

The specific objectives:

  • Objective 1. To develop a nonalcoholic red wine with high phenolic content and sensorial acceptability.
  • Objective 2. To evaluate the chronic effects of the intake of wine polyphenols (average dose 150 mg/day) delivered through a nonalcoholic red wine in the context of a MD in early elderly home-dwelling subjects, and applying participatory research to increase adherence of subjects in the clinical intervention study.

    • Objective 2.1. To identify selective biological phenolic metabolites in human urine samples to be used as biomarkers of nonalcoholic red wine intake.
    • Objective 2.2. To assess the effects of the diet supplementation with red wine polyphenols on the improvement of cognitive ability.
    • Objective 2.3. To assess the effects of the diet supplementation with red wine polyphenols on the improvement of locomotor ability
    • Objective 2.4. To evaluate the effect of the diet supplementation with red wine polyphenols on the improvement of cardiovascular disease (CVD) risk factors.
  • Objective 3. To unravel the underlying mechanisms involved in the potential beneficial effects of red wine polyphenols on aging.

    • Objective 3.1. To evaluate the influence on microbiota composition, function and microbial catabolites.
    • Objective 3.2. To evaluate the impact on inflammation and gut health.
    • Objective 3.3. To evaluate the impact on metabolic pathways related with aging
    • Objective 3.4. To analyze the impact on age-related epigenetic modifications
    • Objective 3.5. To deeply characterize the underlying muscle signalling pathways affected using an animal model of aging.
  • Objective 4. To apply integrative computational analyses for the identification of variables (clinical or gut-related) more determinant for a successful prevention of locomotor and cognitive abilities associated with wine polyphenols.
Read the detailed description

A total of 72 home-dwelling early elderly volunteers (men and women) 60-74 years old will be included in the intervention (36 in each arm of the intervention).

During the study there will be 11 visits in total. Visits will be every 4 weeks form the V1. The study visits will be the following:

  • Screening visit (V0).
  • Basal visit (V1).
  • Visits during intervention (V2, V3, V4, V5, V6, V7, V8, V9).
  • 3-month study visit (V4)
  • 6-month study visit (V7)
  • Telephone visits (V2, V3, V5, V6, V8, V9)
  • Final study visit (V10). In visits V0, V1, V4, V7 and V10 volunteers must present themselves in fasting conditions of 8 hours to obtain fasting blood samples.

    • In addition, future candidates will be provided with the nonalcoholic wine, selected for study and allowed to taste it for one week to check its tolerability and sensory acceptance and thus ensure that candidates can commit to drinking the study wine daily for 9 months and reduce follow-up losses during the intervention.

Basal visit (V1; week 0):

  • Nuclear Magnetic Resonance (NMR) and muscle biopsy (±5 days V1)*.
  • Isokinetic assessment (±5 days V1)*
  • Revision of study clinical history.
  • Vital signs (blood pressure/resting heart rate).
  • Checking the concomitant medication.
  • Anthropometry waist circumference; hip; body weight and composition; height).
  • Checking the physical activity and sedentary habits (IPAQ-E).
  • Checking the quality of life (SF-36 Health survey questionnaire)
  • Checking depression symptoms (Geriatric Depression Scale Questionnaire)
  • Checking MD adherence
  • Checking the cognitive and locomotor abilities
  • Spanish validated of the Mini Mental State Examination (MMSE), Alzheimer disease questionnaire (AD8), Memorey Alteration tets (TAM test), Fototest
  • Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), low physical performance or physical function based on 4 m gait speed, m/s.
  • Blood sample extraction.
  • Ultrasound (muscle mass and abdominal fat).
  • Checking the 3-day dietary record and Food Frequency Questionnaire (FFQ).
  • Collection of feaces samples.
  • Collection of saliva samples.
  • Collection of urine samples.
  • MD guidelines explanation.
  • Schedule the next visit and instructions.
  • Administration of red nonalcoholic wine through opaque bottles to protect from light.

    • In a subsample of n= 15 subjects/group, 5 days before or after the visit V1, volunteers must have a:

      • NMR, in order to measure changes in hippocampal volume, and volume of white matter hyperintense lesions,
      • Muscle biopsys, in order to measure changes in signalling pathways in skeletal muscle,
      • Isokinetics analysis in order to measure changes in muscle function through variables such as torque, work and power.

Telephone visits: (V2 and V3; week 4 and 8):

  • Checking the FFQ
  • Checking changes in concomitant medication
  • Product intake control
  • Record adverse effects
  • Schedule the next visit and instructions.

    3-month study visit (V4; week 12):

    • Revision of study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Anthropometry waist circumference; hip; body weight and composition; height).
    • Checking the physical activity and sedentary habits (IPAQ-E).
    • Checking the quality of life (SF-36 Health survey questionnaire)
    • Checking depression symptoms (Geriatric Depression Scale Questionnaire)
    • Checking MD adherence
    • Checking the cognitive and locomotor abilities
    • Spanish validated of the MMSE, AD8, TAM test, Fototest
    • Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), kg/m2; low physical performance or physical function based on 4 m gait speed, m/s.
    • Blood sample extraction.
    • Ultrasound (quadricep muscle mass and abdominal fat).
    • Checking the Food Frequency Questionnaire, Mediterranean adherence (FFQ).
    • Collection of urine samples.
    • Product intake control
    • Record adverse effects
    • MD guidelines explanation.
    • Schedule the next visit and instructions.
    • Administration of red nonalcoholic wine through opaque bottles to protect from light.

Telephone visits: (V5 and V6; week 16 and 20):

  • Checking the FFQ
  • Checking changes in concomitant medication
  • Product intake control
  • Record adverse effects
  • Schedule the next visit and instructions. 6-month study visit (V7; week 24):

    • Revision of study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Anthropometry waist circumference; hip; body weight and composition; height).
    • Checking the physical activity and sedentary habits (IPAQ-E).
    • Checking the quality of life (SF-36 Health survey questionnaire)
    • Checking depression symptoms (Geriatric Depression Scale Questionnaire)
    • Checking MD adherence
    • Checking the cognitive and locomotor abilities
    • Spanish validated of the MMSE, AD8, TAM test, Fototest
    • Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), kg/m2; low physical performance or physical function based on 4 m gait speed, m/s.
    • Blood sample extraction.
    • Ultrasound (quadricep muscle mass and abdominal fat).
    • Checking the 3-day dietary record and Food Frequency Questionnaire (FFQ).
    • Collection of feaces samples.
    • Collection of saliva samples.
    • Collection of urine samples.
    • MD guidelines explanation.
    • Schedule the next visit and instructions.
    • Administration of red nonalcoholic wine through opaque bottles to protect from light.

Telephone visits: (V8 and V9; week 28, and 32):

  • Checking the FFQ
  • Checking changes in concomitant medication
  • Product intake control
  • Record adverse effects
  • Schedule the next visit and instructions.

Final visit (V10; week 36):

  • NMR and muscle biopsy (±5 days V1)*.
  • Isokinetic assessment (±5 days V1)*
  • Revision of study clinical history.
  • Vital signs (blood pressure/resting heart rate).
  • Checking the concomitant medication.
  • Anthropometry waist circumference; hip; body weight and composition; height).
  • Checking the physical activity and sedentary habits (IPAQ-E).
  • Checking the quality of life (SF-36 Health survey questionnaire)
  • Checking depression symptoms (Geriatric Depression Scale Questionnaire)
  • Checking MD adherence
  • Checking the cognitive and locomotor abilities
  • Spanish validated of the MMSE, AD8, TAM test, Fototest
  • Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), kg/m2; low physical performance or physical function based on 4 m gait speed, m/s.
  • Blood sample extraction.
  • Ultrasound (quadricep muscle mass and abdominal fat).
  • Checking the 3-day dietary record and Food Frequency Questionnaire (FFQ).
  • Collection of feaces samples.
  • Collection of saliva samples.
  • Collection of urine samples. *In a subsample of n= 15 subjects/group, 5 days before or after the visit V10.

    • Nuclear Magnetic Resonance (NMR), in order to measure changes in hippocampal volume, and volume of white matter hyperintense lesions,
    • Muscle biopsys, in order to measure changes in signalling pathways in skeletal muscle,
    • Isokinetics analysis in order to measure changes in muscle function through variables such as torque, work and power.
03

Conditions studied

  • Cognitive Disorders
  • Muscular Disorders, Atrophic

Keywords

  • cognitive impairment
  • locomotor impairment
  • sarcopenia
  • aging
  • mediterrnean diet
  • non-alcoholic wine
  • polyphenols
04

Who can participate

Ages eligible
60 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Men or women between 60-74 years old; Sensory tolerance to red wine; Written provided before the initial screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Men or women >75 years old,
  2. Hypoglucaemiant treatment or type 1 and type 2 diabetes mellitus diagnosed
  3. Anaemia ( ≤13 g/dL in men and ≤12 g/dL in women)
  4. Subjects diagnosed of intestinal disorders such as chron disease, colitis ulcerous, and irritable bowel syndrome
  5. To present a clinical active chronic disease
  6. To present severe sarcopenia
  7. To present cognitive impairment ( ≤ 24 or clinical diagnosis of mild cognitive impairment or dementia)
  8. Dietary allergies to: Mediterranean foods (eg, nuts), sulphytes or nitrates
  9. Use of antioxidants supplements
  10. Regular consumers of red wine who do not agree to change the consumption of red wine with alcohol to nonalcholized wine during the intervention
  11. Chronic alcoholism
  12. Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study
  13. Failure to follow the study guidelines. For participation in the muscle , additional exclusion criteria included: Use of prescription anti- medication; Prescription anticoagulant use (or antiaggregant, or acenocoumarol; Conditions which would reduce healing; or known allergy to lidocaine.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Nonalcoholic red wine group (Intervention group)

    Mediteranean diet + nonalcoholic red wine

    Dietary Supplement: Nonalcoholic red wine group (Intervention group)

  • Placebo comparator
    Drinking water group (Control group)

    Mediterranean diet + drinking water

    Dietary Supplement: Drinking water group (Control group)

Interventions

  • Dietary supplementNonalcoholic red wine group (Intervention group)

    Mediteranean diet + nonalcoholic red wine (300 mL wine/day, equivalent to a daily dose of 150 mg red wine polyphenols/day, during meals)

  • Dietary supplementDrinking water group (Control group)

    Mediterranean diet + drinking water (300 mL/day, during meals)

06

What researchers measure

Primary outcomes

  1. Cognitive function

    The MMSE test for cognitive function. The total test score ranges from 0 (impaired) to 30 (normal) (Beaman et al., 2004).

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  2. Muscle strength

    The muscle strength based on handgrip dynamometry (Jamar dynamometer; Sammons Preston Rolyan, Bolingbrook, IL)

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

Secondary outcomes

  1. Anthropometric measures

    WC: waist circumference (cm) measured by steel measuring tape (at the umbilicus)

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  2. Anthropometric measures

    Height (cm) measured by wall-mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain)

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  3. Anthropometric measures

    Weight (kg) measured by calibrated scale (TANITA MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  4. Anthropometric measures

    BMI (kg/m2) calculated by weight (kg) divided to height (m2).

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  5. Anthropometric measures

    Body composition (Fat mass (% and kg)) measured by calibrated scale (TANITA MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  6. Physical activity compliance

    International physical activity questionnaire for elderly: IPAQ for elderly IPAQ-E Spanish version (Rubio-Castañeda et al., 2017). Higher scores mean a better outcome.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  7. Sedentary habits

    Questionnaire developed by Marshall et al 2010. Higher amount of hours mean bad outcome.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  8. Sleep quality

    Pittsburgh questionnaire (Buysse et al., 1989). The maximum score is 21 points. More than 5 points are considered bad outcomes and sleep problems, and less than 5 points are considered better outcomes and no sleep problems.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  9. Life quality

    SF-36 Health survey questionnaire (Ware \& Sherbourne, 1992). Higher scores mean a better outcome.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  10. Depressive symptoms

    Geriatric Depression Scale Questionnaire (Yesavage et al., 1983). The maximum puntuation is 15. The score is 0-4 no depression, 5-8 mild depression, 9-11 moderate depression and 12-15 severe depression.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  11. Nutritional intake

    3-day dietary record

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  12. Nutritional intake

    FFQ MD adherence to assess food groups intake (Martinez-Gonzalez et al., 2012) Higher scores mean a better outcome.

    Time frame: Visit 1 (week 0), visit 2 (week 4), visit 3 (week 8), visit 4 (week 12), visit 5 (week 16), visit 6 (week 20), visit 7 (week 24), visit 8 (week 28), visit 9 (week 32), visit 10 (week 36))

  13. Nutritional status

    Mini Nutrition Assessment (MNA)

    Time frame: Visit 0 (week -1)

  14. Nutritional status

    Total cholesterol (mmol/L) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  15. Nutritional status

    Albumin (g/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  16. Nutritional status

    Haemoglobin (g/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  17. Nutritional status

    Vitamin D (ng/ml) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  18. Nutritional status

    Vitamin A (ug/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  19. Nutritional status

    Vitamin E (mg/L) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  20. Nutritional status

    Carotenoids (ug/dl) by standardized methods in an automated analyzer (Beckman Coulter-Synchron (Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  21. Cognitive function

    Spanish validated Mini Mental State Examination test (MMSE). The MMSE test various cognitive. The total test score ranges from 0 (impaired) to 30 (normal) (Beaman et al., 2004).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  22. Cognitive function

    AD8. The AD8 (Alzheimer disease questionnaire) aids in identifying cognitive impairment. This test in combination with the Fototest, significantly increases the diagnosis accuracy of both tests (Carnero Pardo et al., 2012). The optimal cut-off point was 3/4.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  23. Cognitive function

    TAM test. TAM test (Memory alteration test) provides efficient and valid screening for amnestic Mild Cognitive Impairment and early stage Alzheimer's disease, and discriminates between them. The cut-off score is of 28 points (Rami et al., 2007).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  24. Cognitive function

    Fototest. The Fototest is useful to identify cognitive impairment and dementia in routine clinical practice. (Carnero Pardo et al., 2007). The cut off points are 25/26 for dementia and 28/29 for cognitive impairment.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  25. Brain volume

    Nuclear Magnetic Resonance (NMR) Total brain volume, hippocampal volume, and volume of white matter hyperintense lesions will be evaluated in a subsample of participants. NMR have allowed important advances in the understanding of age-related brain changes. NMR is a non-invasive instrument that allows the study of the normal aging of individuals at different times of their lives (Barnes et al. 2023).

    Time frame: Visit 1 (week 0), visit 10 (week 36)

  26. Cognitive ability assessment

    BDNF Brain-derived Neutrophic Factor (pg/ml) will be analyzed by Enzyme-linked immunosorbent assay ELISA kit in blood samples

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  27. Skeletal muscle strength

    Isokinetic. Isokinetic test: the evaluation was conducted with an isokinetic dynamometer using a gold standard method (Biodex System 4; Biodex Medical Systems, NewYork, USA) by five repetitions sat two angular velocities (180°s-1, and240°s-1) (Solà et al., 2015). This allows a quantitative evaluation of muscle function through variables such as torque, work and power.

    Time frame: Visit 1 (week 0), visit 10 (week 36)

  28. Muscle mass, wasting and turnover

    Muscle mass (skeletal muscle mass (kg)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  29. Muscle mass, wasting and turnover

    Muscle mass (appendicular skeletal muscle mass (kg)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  30. Muscle mass, wasting and turnover

    Muscle mass (skeletal muscle mass index (kg/m2)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  31. Muscle mass, wasting and turnover

    Muscle mass (appedicular skeletal muscle mass index (kg/m2)) assessed by Bioimpedance TANITA (MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  32. Muscle mass, wasting and turnover

    Muscle mass assessed by ultrasound (VINNO 5 (Vinno (Suzhou) Co., Ltd., China)

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  33. Muscle mass, wasting and turnover

    Creatine kinase (U/L) assessed by enzymatic assays in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  34. Muscle mass, wasting and turnover

    Cystatin-C (mg/L) assessed by enzymatic assays in a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain).

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  35. Muscle mass, wasting and turnover

    Serum Myostatin (ng/ml) assessed by commercial ELISA kits (Muscari et al., 2023)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  36. Muscle mass, wasting and turnover

    Serum Follistatin (ng/ml) assessed by commercial ELISA kits (Muscari et al., 2023)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  37. Physical performance

    Gait speed (m/s) assessed by the length of the walking course divided by the time (Ladang et al., 2023).

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  38. Signalling pathways in skeletal muscle

    Muscle gene expression. A muscle biopsy (200-225 mg) will be obtained from a subgroup of volunteers (n=15/group) by trained physicians (Harper et al., 2021). After collection, these samples will be immediately snap frozen in liquid nitrogen and stored at -80°C prior to analysis. To confirm RNA sequencing results obtained in the animal model of age-associated sarcopenia (transcriptomic approach that will be carried out in gastrocnemius skeletal muscle as described in task 5.2), real-time gene expression analysis (qPCR) will be performed, as previously described (Pérez-Matute et al., 2016).

    Time frame: Visit 1 (week 0), visit 10 (week 36)

  39. Biological age marker (Aging biomarker)

    Serum N-terminal pro-brain natriuretic peptide (NT-proBNP) (pg/ml) in blood samples (Muscari et al., 2023) is used to diagnose and establish prognosis for heart failure and is a promising biomarker of biological age as it correlates with chronological age and predict life span better than chronological age.

    Time frame: Visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36)

  40. Glucose homeostasis

    FBG (mmol/L) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  41. Glucose homeostasis

    Insulin (IU/mL) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  42. Glucose homeostasis

    HGBA1c (%) assessed by standardized methods in an automated analyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  43. Glucose homeostasis

    HOMA index calculated (Winell et al., 2010) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  44. Glucose homeostasis

    IGF-1 (ng/ml) levels were measured using Human IGF-1 Quantikine ELISA Kit (Pérez-Matute et al., 2022) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  45. Lipid profile

    Total cholesterol (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  46. Lipid profile

    HDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  47. Lipid profile

    LDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  48. Lipid profile

    VLDLc (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  49. Lipid profile

    Total TG (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  50. Lipid profile

    NEFA (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  51. Lipid profile

    ApoA1 (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  52. Lipid profile

    ApoB100 (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  53. Lipid profile

    Apo B100/Apo A1 ratio in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  54. Lipid profile

    Lp (a) (mg/dL) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  55. Stress Response and Mitochondria

    GDF15 (pg/mL) Growth differentiating factor 15 is recgonized in mitochondria dysfunction, and as biomarker of aging (Justice et al., 2018) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  56. Oxidative markers

    OxLDL (ug/mL) assessed by commercial ELISA in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  57. Oxidative markers

    MetSO/Met (ng/mL) assessed by commercial ELISA in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  58. Oxidative markers

    SOD (U/g Hb) 20uL (abcam) in plasma EDTA blood samples assessed by enzymatic assays (Hissin et al., 1976)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  59. Oxidative markers

    GSHPx (nmol/mL) 50uL (abcam) plasma EDTA blood samples enzymatic assays (Hissin et al., 1976)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  60. Oxidative markers

    CoQ10 (ug/mL) in blood samples assessed by HPLC

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  61. Inflammation markers

    IL-6 (pg/mL) assessed by immunoturbidimetry on an autoanalyzer (Roche Diagnostics Systems, Madrid, Spain) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  62. Inflammation markers

    hsCRP (mg/L) assessed by immunoturbidimetry on an autoanalyzer (Roche Diagnostics Systems, Madrid, Spain) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  63. Inflammation markers

    TNFRII (pg/mL) assessed by commercial ELISA in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  64. Inflammation markers

    Adiponectin (ug/mL) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  65. Inflammation markers

    Uric acid (mg/dL) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  66. Vascular parameters

    Systolic and diastolic blood pressure (SBP and DBP) (mm Hg) and pulse pressure (PP) (mm Hg) assessed by automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain).

    Time frame: Visit 0, visit 1Visit 0 (week -1), visit 1 (week 0), visit 4 (week 12), visit 7 (week 24), visit 10 (week 36), visit 4, visit 7, visit 10

  67. Biomarkers of endothelial dysfunction

    E-selectin (CD62E) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  68. Biomarkers of endothelial dysfunction

    P-selectin (CD62P) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  69. Biomarkers of endothelial dysfunction

    ICAM-1 (CD54) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  70. Biomarkers of endothelial dysfunction

    VCAM-1 (CD106) (ng/mL) assessed by Commercial ELISA and multi-analyte ELISArray kits as described in our previous work (Catalán et al., 2015) in blood samples

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  71. Faecal microbial composition

    Metataxonomic profile.

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  72. Faecal microbial function

    Microbial functional profile

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  73. Faecal metabolome

    SCFA acetic, butyric, propionic, isobutyric, valeric, isovaleric and caproic acid and phenol colonic metabolites

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  74. DNA methylation

    Epigeneitc age. Total genomic DNA will be extracted from saliva samples using the Norgen Saliva DNA Isolation Kit.

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  75. Gut permeability determined on plasma

    Zonulin (ng/mL). Human zonulin levels will be quantified using an ELISA kit (Cusabio® Technology Llc, Houston, TX, USA)

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

  76. Biomarkers of wine intake compliance

    Quantification of urine phenol metabolites in human elderly

    Time frame: Visit 1 (week 0), visit 7 (week 24), visit 10 (week 36)

07

Study locations

1 of 3 sites recruiting
  • Instituto de Ciencias de la Vid y del Vino-ICVV (Consejo Superior de Investigaciones Científicas-CSIC, Universidad de La Rioja, Gobierno de La Rioja)
    Logroño, Spain, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Lyfestyle, Microbiota and Health Unit, Health Sciences Faculty, University of La Rioja
    Logroño, Spain, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut)
    Reus, Spain 43201, Spain
    Recruiting
    • Rosa Solà Alberich, Professor · Contactrosa.sola@urv.cat · +34 977 759 369
    • Anna Pedret Figuerola, Dr. · Contactanna.pedret@urv.cat · +34 977 759 375
    • Elisabet Llauradó, Dr. · Sub investigator
    • Rosa Maria Valls, Dr. · Sub investigator
    • Judit Queral, Dr. · Sub investigator
    • Maria Besora, Dr. · Sub investigator
    • Claudia Jiménez, Mis. · Sub investigator
08

References and documents

Publications

  • Jimenez-Ten Hoevel C, Girones I, Nicolas-Marzo J, Besora-Moreno M, Queral J, Valls RM, Perez-Matute P, Motilva MJ, Llaurado E, Sola R, Pedret A. Ultrasound-assessed abdominal fat distribution and its relation to sarcopenia parameters in community-dwelling young older adults: a cross-sectional study. Front Endocrinol (Lausanne). 2026 Jun 19;17:1888492. doi: 10.3389/fendo.2026.1888492. eCollection 2026. PubMed 42404338 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 18 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 11, 2025
StartActual
Mar 26, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Apr 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06871384
Lead sponsor
University Rovira i Virgili
Collaborators
National Research Council, Spain
Responsible party
Rosa Sola (Full Professor, Dr. Rosa Solà Alberich, University Rovira i Virgili) — Principal investigator
First posted
Mar 11, 2025
Start date
Mar 26, 2025
Primary completion
Sep 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Rosa Solà Alberich, Professor
Contact
rosa.sola@urv.cat
+34 977 759 369
Anna Pedret Figuerola, Dr.
Contact
anna.pedret@urv.cat
+34 977 759 375
Rosa Solà Alberich, Professor
principal investigator · Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, NFOC-Salut group, 43201 Reus, Spain Institut Investigació Sanitària Pere i Virgili (ISPV), 43204, Reus, Spain Hospital Universitari Sant Joan de Reus, 43204, Reus, Spain
Anna Pedret Figuerola, Dr.
principal investigator · Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, NFOC-Salut group, 43201 Reus, Spain

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion